27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
The following are the M&A deals, rumors and chatter circulating on Wall Street for Monday, October 2, 2017.
CenturyLink Wins Conditional US Antitrust Approval for Purchase Of Level 3
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
The Approval:
The U.S. Department of Justice on Monday agreed to approve CenturyLink Inc (NYSE:CTL) pending acquisition of Level 3 Communications, Inc. (NYSE:LVLT) subject to conditions, including court approval of certain provisions. The combined company is required to divest certain Level 3 metro network assets and 24 strands of dark fiber connecting 30 specified city-pairs across the country.
Level 3 Communications closed Monday at $53.94 and traded at $55.89 after-hours.
Unilever to Acquire Mae Terras
The Deal:
FREE REPORT: How To Learn Options Trading Fast
In this special report, you will learn the four best strategies for trading options, how to stay safe as a complete beginner, a 411% trade case study, PLUS how to access two new potential winning options trades starting today.Claim Your Free Report Here.
Unilever (NYSE:UL) (NYSE:UN) announced it has signed an agreement to acquire Brazilian natural and organic food business Mãe Terra. Closing is subject to regulatory approvals.
Terms were not disclosed.
Unilever closed at $57.92, down 4 cents.
Dimension Therapeutics Board Says Ultragenyx's $6/Share Proposal is a 'Superior Proposal'
The Offer:
Dimension Therapeutics Inc (NASDAQ:DMTX) announced that Dimension's Board of Directors has determined that an unsolicited proposal of $6.00 per share, from Ultragenyx Pharmaceutical Inc (NASDAQ:RARE), constitutes a "Superior Proposal" as defined in Dimension's existing merger agreement with REGENXBIO Inc. (NASDAQ:RGNX), dated Aug. 24, 2017. Ultragenyx has now delivered a binding acquisition agreement, subject to acceptance by Dimension
REGENXBIO has agreed that it's not exercising its right under the merger agreement, to potentially match or exceed Ultragenyx's proposal.
Dimension Therapeutics closed at $5.90, down 10 cents.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.